- Home
- HOOK vs MRM Comparison
HOOK vs MRM Comparison
Compare HOOK & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- MRM
- Stock Information
- Founded
- HOOK 2011
- MRM 2000
- Country
- HOOK United States
- MRM Japan
- Employees
- HOOK N/A
- MRM N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- MRM Other Consumer Services
- Sector
- HOOK Health Care
- MRM Consumer Discretionary
- Exchange
- HOOK Nasdaq
- MRM Nasdaq
- Market Cap
- HOOK 11.9M
- MRM 10.4M
- IPO Year
- HOOK 2019
- MRM 2020
- Fundamental
- Price
- HOOK $0.89
- MRM $1.25
- Analyst Decision
- HOOK Hold
- MRM
- Analyst Count
- HOOK 3
- MRM 0
- Target Price
- HOOK $4.50
- MRM N/A
- AVG Volume (30 Days)
- HOOK 155.2K
- MRM 25.7K
- Earning Date
- HOOK 08-11-2025
- MRM 05-20-2025
- Dividend Yield
- HOOK N/A
- MRM N/A
- EPS Growth
- HOOK N/A
- MRM 27.65
- EPS
- HOOK N/A
- MRM 0.18
- Revenue
- HOOK $9,351,000.00
- MRM $52,786,758.00
- Revenue This Year
- HOOK N/A
- MRM N/A
- Revenue Next Year
- HOOK N/A
- MRM N/A
- P/E Ratio
- HOOK N/A
- MRM $6.56
- Revenue Growth
- HOOK N/A
- MRM 21.55
- 52 Week Low
- HOOK $0.72
- MRM $0.34
- 52 Week High
- HOOK $6.00
- MRM $8.39
- Technical
- Relative Strength Index (RSI)
- HOOK 19.78
- MRM 41.06
- Support Level
- HOOK $0.89
- MRM $1.11
- Resistance Level
- HOOK $0.95
- MRM $1.32
- Average True Range (ATR)
- HOOK 0.06
- MRM 0.10
- MACD
- HOOK -0.01
- MRM -0.02
- Stochastic Oscillator
- HOOK 7.11
- MRM 40.06
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.